Targeting ALK, ROS1, and BRAF Kinases

Journal of Thoracic Oncology

Volumn 7, Issue 16 SUPPL. 5, 2012, Pages

  Doebele, Robert C ^a   Camidge, D Ross ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; AP 26113; B RAF KINASE; CH 5424802; CRIZOTINIB; DACOMITINIB; LDK 378; PROTEIN TYROSINE KINASE; ROS1 ENZYME; UNCLASSIFIED DRUG;

ARTICLE; DRUG TARGETING; GENE; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

EID: 84870426431     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31826df05e     Document Type: Article

References (11)

1. Weinstein IB. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002;297:63-64.
2. Kris MG, Giaccone G, Davies A, et al. Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma. J Thorac Oncol 2006;1(9 Suppl):S32-S36.
3. Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small-cell lung cancer. Clin Cancer Res 2012;18:1472-1482.
4. Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 2012;4:120ra17.
5. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008;14:4275-4283.
6. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30:863-870.
7. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18:378-381.
8. Davies KD, Le AT, Theodoro MF, et al: Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer. Clin Cancer Res 2012;18:4570-4579.
9. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011;29:2046-2051.
10. Chapman PB, Hauschild A, Robert C, et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-2516.
11. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012;483:100-103.